Home » Stocks » XENE

Xenon Pharmaceuticals Inc. (XENE)

Stock Price: $11.40 USD 0.06 (0.53%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $11.52 +0.12 (1.05%) Nov 27, 3:42 PM

Stock Price Chart

Key Info

Market Cap 399.08M
Revenue (ttm) 30.35M
Net Income (ttm) -26.99M
Shares Out 35.01M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $11.40
Previous Close $11.34
Change ($) 0.06
Change (%) 0.53%
Day's Open 11.43
Day's Range 10.96 - 11.52
Day's Volume 107,602
52-Week Range 7.00 - 18.45

More Stats

Market Cap 399.08M
Enterprise Value 208.94M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 35.01M
Float n/a
EPS (basic) -0.88
EPS (diluted) -0.83
FCF / Share -0.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 806,384
Short Ratio 6.74
Short % of Float n/a
Beta 1.34
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 13.15
PB Ratio 2.29
Revenue 30.35M
Operating Income -29.98M
Net Income -26.99M
Free Cash Flow -17.68M
Net Cash 190.14M
Net Cash / Share 5.43
Gross Margin -105.51%
Operating Margin -98.78%
Profit Margin -88.90%
FCF Margin -58.26%
ROA -12.57%
ROE -21.74%
ROIC -19.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$22.71*
(99.21% upside)
Low
22.0
Current: $11.40
High
24.0
Target: 22.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue6.83-0.311.8015.5828.3727.3614.316.92
Revenue Growth---82.75%-88.43%-45.09%3.71%91.19%106.82%-
Gross Profit6.83-0.311.8015.5828.3727.3614.316.92
Operating Income-42.82-38.04-32.58-24.82-9.3611.119.71-3.15-12.11
Net Income-41.60-34.50-30.70-23.00-15.7513.0212.03-4.30-11.99
Shares Outstanding25.9419.4317.9915.4914.283.171.341.331.32
Earnings Per Share-1.54-1.63-1.72-1.48-1.103.281.91-3.24-9.06
EPS Growth-----71.73%---
Operating Cash Flow-4.63-34.72-28.73-19.57-18.100.27-3.3245.57-13.69
Capital Expenditures-1.24-0.51-0.32-0.28-0.55-1.53-0.15-0.52-0.29
Free Cash Flow-5.87-35.23-29.04-19.85-18.65-1.26-3.4745.05-13.98
Cash & Equivalents14111943.6764.1558.6584.0449.2860.16-
Total Debt16.4515.016.80----1.67-
Net Cash / Debt12510436.8664.1558.6584.0449.2858.50-
Assets14812246.1267.4963.9587.4254.4963.31-
Liabilities55.7219.1310.193.592.9214.6413350.68-
Book Value91.9810335.9363.9061.0372.78-78.37-89.87-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xenon Pharmaceuticals Inc.
Country Canada
Employees 100
CEO Simon Neil Pimstone

Stock Information

Ticker Symbol XENE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XENE
IPO Date November 5, 2014

Description

Xenon Pharmaceuticals, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.